Generics BulletinHBW InsightIn VivoMedtech InsightPink SheetScrip

Generics Bulletin

Medtech Insight

Biogen Asks Medicare For Aduhelm Coverage With Real-World Evidence Development

Feb 11 2022

• By M. Nielsen Hobbs

MRI scan of human brain — • Source: Alamy

Related Content

Biogen Pledges Aduhelm Confirmatory Data By 2026, Renewing Spotlight On FDA’s Lengthy Original Plan

Dec 16 2021

Medicare’s CED For Alzheimer’s Drugs May Exceed Statutory Authority, Former HHS Attorneys Say

Feb 11 2022

Aduhelm Medicare Coverage: House Republicans Push For CMS To Collaborate With US FDA

Feb 10 2022

Biogen’s Plea To Medicare: Just Cover The Aduhelm Clinical Trial Population

Jan 13 2022

Medicare Draft NCD For Alzheimer's Drugs: When 'Reasonable And Necessary' And 'Safe And Effective' No Longer Align

Jan 12 2022

Related Companies

Biogen, Inc.

Additional Topics

United States Real-World Evidence Reimbursement Policy Government Payers Market Access BioPharmaceutical Neurology

More from Medicare

More from Government Payers

Twitter feed RSS feed RSS feed

About Us

Meet the TeamOpens in new window
RSS FeedOpens in new window

Contact Us

Customer Service
SubscribeOpens in new window
AdvertisingOpens in new window
Feedback

Terms and ConditionsOpens in new window

Privacy PolicyOpens in new window

Copyright © 2025 Pharma Intelligence UK Limited (Citeline), a Norstella company Pharma Intelligence UK Limited is a company registered in England and Wales with company number 13787459 whose registered.